Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp, a leading global life sciences company, is the first commercial laboratory in the U.S. to offer quantitative testing for gluten in stool samples. This innovative test, developed in collaboration with Immundiagnostik, Inc., allows individuals to accurately assess unintentional gluten consumption. With increasing awareness of celiac disease and non-celiac gluten sensitivity (NCGS), the demand for reliable testing is rising. The new test aims to provide healthcare providers and patients with critical information to better manage gluten exposure and dietary choices.
Labcorp (NYSE: LH) has announced a strategic partnership with Prisma Health, South Carolina's largest health system, to enhance laboratory services for patients and physicians. The collaboration involves Labcorp acquiring certain assets from Prisma's outreach lab business and providing technical support to improve hospital laboratory operations. This initiative aims to expand access to laboratory testing across South Carolina, including same-day STAT testing, and is anticipated to close in the second half of 2022, although specific transaction terms remain undisclosed.
Walgreens and Labcorp have launched the nationwide availability of the Pixel by Labcorp® COVID-19 at-home collection kit, accessible at no cost to eligible individuals via Labcorp OnDemand™. This initiative, in partnership with the U.S. Department of Health and Human Services, aims to enhance testing accessibility for underserved communities. Walgreens President John Standley emphasized the importance of reducing healthcare barriers, particularly for uninsured populations. The program complements Walgreens' existing free drive-thru testing at over 7,000 locations and contributes to broader healthcare efforts amidst evolving COVID-19 conditions.
Labcorp (NYSE: LH) has successfully completed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics. This strategic acquisition enhances Labcorp's liquid biopsy capabilities and expands its oncology portfolio, specifically its next-generation sequencing (NGS)-based genomic profiling products. The deal aims to improve patient outcomes in oncology. The definitive agreement was initially announced on December 23, 2021, highlighting Labcorp's commitment to advancing its diagnostics and drug development capabilities.
Labcorp (NYSE: LH) announced its 2021 Q4 and full-year results, reporting revenues of $4.06 billion for Q4, down 9.7% year-over-year, and $16.12 billion for the full year, a 15.3% increase. Diluted EPS fell to $5.75 in Q4 from $9.54 a year prior, while full-year adjusted EPS rose to $28.52 from $23.94. The company expects a robust outlook for 2022, targeting adjusted EPS between $17.25 and $21.25 and free cash flow of $1.7 to $1.9 billion. Labcorp's oncology position will strengthen with the acquisition of Personal Genome Diagnostics and a key partnership with Ascension.
Labcorp (NYSE: LH) has announced a strategic collaboration with Ascension, enhancing access to lab services across 10 states in the U.S. Labcorp will manage Ascension’s hospital labs and acquire select outreach lab assets. This partnership aims to improve patient care by leveraging Labcorp's expertise in areas like oncology and neurology. The transactions, pending regulatory approval, are expected to close in the first half of 2022, marking a significant step in Labcorp's mission to innovate healthcare.
Labcorp (NYSE: LH) has announced the opening of a new diagnostics laboratory in South Bend, Indiana, aimed at enhancing service levels for patients and physicians in the region. This 25,000-square-foot facility includes advanced capabilities for microbiology testing and STAT testing, expediting results for urgent tests. Currently employing 100 individuals, the lab aims to improve patient diagnoses and outcomes. The opening builds on Labcorp's prior acquisition of South Bend Medical Foundation’s diagnostic business in October 2019, further expanding service access in Indiana and surrounding states.
Labcorp (NYSE: LH) has launched Labcorp OnDemand, a digital platform allowing consumers to purchase popular tests online and choose to collect samples from home or visit one of 2,000 Labcorp Patient Service Centers. The platform includes tests for wellness, allergies, COVID-19, women's health, and fertility, facilitating better health management. Tests are available with zero upfront costs for eligible individuals. The company plans to expand its offerings through healthcare providers and employers later this year.
Big Health announces Gabriela Perez as its new Chief Commercial Officer to lead global commercial growth and strategy. With over 20 years of experience in healthcare technology, Perez previously managed significant growth at Ovia Health, which was acquired by Labcorp (NYSE: LH) in August 2021. She also contributed to Best Doctors, acquired by Teladoc Health (NYSE: TDOC) in June 2017. Under her leadership, Big Health aims to enhance coverage and reimbursement for digital therapeutics, leveraging its innovative products proven effective in mental health treatment.
Summary not available.